Silence Therapeutics plc (XRP2.F)

Compare

5.95

+0.05

(+0.85%)

As of 9:07:20 AM GMT+1. Market Open.

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Key Insights Given the large stake in the stock by institutions, Silence Therapeutics' stock price might be vulnerable...

Simply Wall St. 1 hour ago

SLN

SLNCF
Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other oversold global stocks. ‘There are decades where nothing happens, and there are weeks where decades happen” is apt when starting a […]

Insider Monkey 23 days ago

SLNCF

^FTSE
Insider Traders Lose UK£124k As Silence Therapeutics Drops

Insiders who bought UK£187.6k worth of Silence Therapeutics plc's ( NASDAQ:SLN ) stock at an average buy price of...

Simply Wall St. 27 days ago

SLN

SLNCF
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

LONDON, December 09, 2024--Silence Therapeutics plc ("Silence" or the "Company") (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California.

Business Wire last month

SLN

SLNCF
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

LONDON, November 26, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET.

Business Wire last month

SLN

SLNCF
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

Zacks last month

SLNCF

AMGN
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented at the American Heart Association (AHA) Scientific Sessions. Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted redu

Benzinga last month

SLNCF
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

LONDON, November 18, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were prese

Business Wire last month

SLN

SLNCF
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics ( NASDAQ:SLN ) Third Quarter 2024 Results Key Financial Results Revenue: UK£1.14m (down 59% from...

Simply Wall St. last month

SLN

SLNCF
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

LONDON, November 14, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights.

Business Wire last month

SLN

SLNCF
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, November 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT.

Business Wire last month

SLN

SLNCF
Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical industry remains a hub of […]

Insider Monkey 2 months ago

SLNCF
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Silence...

Simply Wall St. 2 months ago

SLN

SLNCF
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

LONDON, August 27, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the following conferences:

Business Wire 4 months ago

SLN

SLNCF
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...

Simply Wall St. 4 months ago

SLN

SLNCF
Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics ( NASDAQ:SLN ) Second Quarter 2024 Results Key Financial Results Revenue: UK£598.0k (down 93% from...

Simply Wall St. 4 months ago

SLN

SLNCF
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

LONDON, August 15, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2024 and reviewed recent business highlights.

Business Wire 4 months ago

SLN

SLNCF
The 3 Best Gene Editing Stocks to Buy in August 2024

Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030. Efficiencies could contribute $1.5 trillion to the enterprise value of companies pursuing these technologies. Over the next five years or so, gene-editing using CRISPR-based processes to target and cure rare diseases and chronic conditions will expand at a 46% CAGR. Wood seeks out opportunities to generate phe

InvestorPlace 5 months ago

CRSP

SLNCF

ALNY
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks

Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are nonetheless guesses. Analyst price targets are short-term in nature. They tend to look out for 12 months or so. Investors shouldn’t weigh too much on these opinions as stock prices can be volatile over such short periods. An investor should seek to own a stock f

InvestorPlace 5 months ago

LI

VKTX

SLNCF
Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain

Key Insights Institutions' substantial holdings in Silence Therapeutics implies that they have significant influence...

Simply Wall St. 5 months ago

SLN

SLNCF

Performance Overview

Return	XRP2.F	S&P 500
YTD	-9.16%	-1.12%
1-Year	-63.27%	+22.80%
3-Year	-71.12%	+24.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Silence Therapeutics plc (XRP2.F)

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

Insider Traders Lose UK£124k As Silence Therapeutics Drops

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

The 3 Best Gene Editing Stocks to Buy in August 2024

Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks

Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain

Performance Overview